Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

While Mounjaro offers clinicians a newer option for patients, the medicine alone is not a solution. "The rise in obesity and type 2 diabetes presents a significant public health challenge in India.

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

Wegovy launch in India challenges Eli Lilly's Mounjaro Analysts say Wegovy priced competitively to Mounjaro Novo faces competition from generic drugmakers Wegovy 0.25 mg, 0.5 mg and 1 mg available ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May ...

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a majority of the population ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management. Approved by CDSCO, it targets GIP and GLP-1 receptors, aiming to improve ...